Periprocedural bridging management of anticoagulation

Circulation

Volumn 126, Issue 4, 2012, Pages 486-490

  Wysokinski, Waldemar E ^a   McBane, Robert D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; RIVAROXABAN; WARFARIN;

ABDOMINAL HYSTERECTOMY; AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; COLONOSCOPY; CREATININE CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ELECTIVE SURGERY; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LOWER EXTREMITY DEEP VEIN THROMBOSIS; MALE; OVARIECTOMY; OVARY CANCER; POLYPECTOMY; POPLITEAL VEIN; PRIORITY JOURNAL; STROKE; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; COLONOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYSTERECTOMY; MALE; PERIOPERATIVE CARE; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN; WITHHOLDING TREATMENT;

EID: 84864249328     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.092833     Document Type: Article

References (24)

1. Waterman AD, Banet G, Milligan PE, Frazier A, Verzino E, Walton B, Gage BF. Patient and physician satisfaction with a telephone-based anticoagulation service. J Gen Intern Med. 2001;16:460-463. (Pubitemid 34208922)
2. Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study). http://clinicaltrials.gov/ct2/show/NCT00786474. Accessed June 28, 2012.
3. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004;125:1642-1650. (Pubitemid 38648392)
4. McBane RD, Attaya H, Shah N, Wysokinski WE, Van Houten H, Heit JA. Periprocedural anticoagulation management of mechanical prosthetic heart valve patients. J Am Coll Cardiol. 2011;57:E1381.
5. Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009;7:552-558.
6. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 2009;124:300-305.
7. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83:639-645. (Pubitemid 351810563)
8. McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:442-448.
9. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):e326S-e350S.
10. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e1-e142.
11. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with lowmolecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005;94:528-531. (Pubitemid 41300847)
12. Tafur A, McBane R, Wysokinski WE, Slusser J, Hodge D, Heit JA. Predictors of periprocedural bleeding among patients on chronic anticoagulation. J Thromb Haemost. 2012;10:261-267.
13. Douketis JD, Johnson JA, Turpie AG. Lowmolecular-weight heparin as bridging anticoagulation during interruption of warfarin. Arch Intern Med. 2004;164:1319-1326.
14. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S, Standardized low-molecularweight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery. Circulation. 2009;119:2920-2927.
15. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AGG, Bates SM, Desjardins CL, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-1663. (Pubitemid 39297990)
16. Hammerstingl C, Tripp C, Schmidt H, von der Recke G, Omran H. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis. 2007;16:285-92. (Pubitemid 46887057)
17. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211-2218. (Pubitemid 47617873)
18. Attaya H, Wysokinski WE, Bower T, Litin S, Daniels PR, Slusser J, Heit JA, McBane RD. Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. J Thromb Thrombolys. In press.
19. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365: 883-891.
21. van Ryn J Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haem. 2010;103: 1116-1127.
22. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573-1579.
23. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M. Periprocedural bleeding and thromboembolic events with Dabigatran compared with Warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343-348.
24. Tafur AJ, Wysokinski WE. McBane R, Wolny E, Sutkowska E, Litin SC, Daniels PR, Slusser JP, Hodge DO, Heit JA. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Onc. April 3, 2012. doi: 10.1093/annonc/mds058.